Strict carbohydrate restriction enables volume-based FDG-PET/CT to outperform SUVmax for risk stratification in cardiac sarcoidosis.

Yoshimitsu Fukushima, Takahiro Ando, Kenji Yodogawa, Tsutomu Igarashi, Hiromitsu Hayashi, Shinichiro Kumita

Abstract read

In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yoshimitsu FukushimaDepartment of Radiology, Nippon Medical School, Tokyo, Japan.

Takahiro AndoDepartment of Radiology, Nippon Medical School, Tokyo, Japan.

Kenji YodogawaDepartment of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.

Tsutomu IgarashiDepartment of Ophthalmology, Nippon Medical School, Tokyo, Japan.

Hiromitsu HayashiDepartment of Radiology, Nippon Medical School, Tokyo, Japan.

Shinichiro KumitaDepartment of Radiology, Nippon Medical School, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: FDG-PET/CT SUVmax reflects focal metabolic intensity but not the patchy inflammatory burden of cardiac sarcoidosis (CS). We evaluated whether volume-based total cardiac metabolic volume (tCMV) and total cardiac metabolic activity (tCMA), measured after optimized suppression, predict long-term major adverse cardiac events (MACE) better than SUVmax. Methods: Forty-eight consecutive patients with CS classified by JCS 2016 criteria underwent FDG-PET/CT after 24-h strict carbohydrate restriction without high-fat supplementation and delayed cardiac imaging at 120 min. tCMV, tCMA, and SUVmax were quantified at a fixed SUV threshold of 1.70. MACE was assessed over a median of 7.3 years. DeLong tests and Firth-penalized Cox regression evaluated prognostic performance. Results: MACE occurred in 18 of 48 patients (37.5%). tCMA (AUC, 0.766) and tCMV (AUC, 0.764) outperformed SUVmax (AUC, 0.606; DeLong Conclusions: Under optimized suppression, tCMA captured global inflammatory burden rather than focal intensity and improved MACE risk stratification in CS. Volume-based quantification may complement SUVmax and conventional risk markers, pending external validation.

Indexed as

18F-FDG PET/CTCarbohydrate restrictionCardiac sarcoidosisDelayed imagingRisk stratificationVolume-based quantification

Identifiers

PMID42436824

DOI10.1016/j.ijcha.2026.101968

PMCPMC13355662

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.